Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of oral brepocitinib in adults with lichen planopilaris, a condition affecting the scalp. This Phase 23 trial aims to understand how well this medication works compared to a placebo in treating active and symptomatic lichen planopilaris. The study is sponsored by Priovant Therapeutics, Inc. and uses a randomized, double-blind design to ensure reliable results. Participants are randomly assigned to receive either oral brepocitinib or a placebo. The study is conducted in parallel groups, with neither the participants nor the researchers knowing who receives the active drug or placebo. The treatment period lasts 24 weeks, during which the participants take the assigned oral medication. The main goal is to measure improvement in the Investigator Global Assessment IGA score by Week 24. Throughout the study, participants will be regularly monitored for safety and symptom changes. Researchers will assess the proportion of participants who achieve significant improvement in their IGA scores at Week 24 and track changes in symptom severity using a numerical rating scale. The total study duration extends until July 2029, allowing for thorough evaluation of treatment effects and safety over time.
Actively Recruiting
Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.
Actively Recruiting
Researchers are evaluating the Freenome Multiomics Blood Test as a new way to screen for lung cancer in people at high risk. This observational study includes adults aged 50 and older who are current or former smokers with a significant smoking history. The goal is to see how well this blood test works alongside the standard Low-Dose Computed Tomography LDCT screening to detect lung cancer early. Participants will provide a blood sample of 50 ml that will be tested and stored by Freenome or its designee. They will also undergo a standard LDCT chest scan, ideally on the same day as the blood draw or within 45 days afterward. The study collects additional information such as medical history, lifestyle, environmental exposures, and results from diagnostic tests related to lung cancer detection. Participants will be monitored for at least 24 months following their baseline chest CT scan to track health outcomes. Researchers will review clinical data, imaging reports, and lab results during this period. The main outcome measured is the blood tests sensitivity and specificity in detecting lung cancer at 12 months, with additional measurements at 24 months. The study may end early if participants withdraw or pass away.
Actively Recruiting
Researchers are studying a medicine called elranatamab to treat multiple myeloma MM, a type of cancer. This study compares elranatamab with other common combination therapies for people with MM that has returned or not responded to previous treatments, including anti-CD38 antibody and lenalidomide. The study is sponsored by Pfizer and is a phase 3, open-label trial evaluating treatment options for adults with relapsed or refractory MM. Participants will be randomly assigned to receive either elranatamab alone or one of several combination therapies chosen by the study doctor. Elranatamab is given as a shot under the skin at the clinic about once a week, which may reduce in frequency later. Combination therapies include two to three different medicines taken orally or by injection at the clinic, with dosing schedules depending on the selected regimen. Treatment continues until the disease no longer responds. During the study, participants will have regular clinic visits to monitor their response and safety while receiving treatment. After treatment ends, follow-up will be done by phone or clinic visits. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, duration of response, and quality of life over approximately five years. Safety and laboratory tests will also be monitored throughout and shortly after treatment completion.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the performance and safety of the Maxx Orthopedics Freedom Total Knee System with a new femoral component made from polyether-ether-ketone PEEK in patients with knee osteoarthritis. This investigational device exemption IDE study focuses on comparing this PEEK femoral component to a similar design made from cobalt-chromium CoCr alloy. The study aims to monitor how well the device works and its safety over time in adults with moderate knee impairment. Participants will undergo primary total knee arthroplasty using the Freedom Total Knee System with the PEEK femoral component. This is a single-arm, multi-center trial where 200 patients will receive the PEEK device. Their results will be compared to matched historic controls from a product registry. The study uses FDA-approved instrumentation to assist the knee surgery and includes follow-up to assess post-operative care, complications, and device performance. During the study, participants will be evaluated through clinical visits and assessments at multiple time points up to 24 months after surgery. Researchers will use measures such as the Knee Society Score, Knee Injury and Osteoarthritis Outcome Score, PROMIS Global-10, Visual-Analog Scale, and Forgotten Joint Score to monitor outcomes. Patient records will be reviewed for any complications or re-operations. The total study duration extends from surgery through 24 months of follow-up to assess long-term device safety and function.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating changes in skin surface appearance and acne severity in adults with acne-prone skin using a standardized series of treatments with PRX S, a topical cosmetic product designed for oily and acne-prone skin. This pilot cohort study explores whether five in-office PRX S sessions, combined with a prescribed home care regimen, affect objective skin parameters, clinician-rated acne severity, and participant-reported quality of life. Participants will receive five PRX S topical cosmetic treatment sessions every two weeks over approximately eight weeks. The treatment is applied by trained professionals using a non-ablative technique tailored to skin type. Alongside these sessions, participants will use a standardized home care regimen consisting of a nourishing cream and a balancing cream provided by the sponsor. The study includes follow-up visits to monitor changes after completing the treatment cycle. Participants will undergo complexion analysis and clinical assessments at baseline, mid-cycle week 6, and at the end of follow-up week 10. Researchers will measure changes in skin pores, spots, redness, porphyrins, and texture, as well as acne severity scores and quality of life related to skin condition. Treatment tolerability will also be monitored throughout the study. The total participation lasts about ten weeks, including treatment and follow-up visits.
Actively Recruiting
Researchers are evaluating povorcitinib, an oral tablet, for its pharmacokinetics, safety, and efficacy in adolescents aged 12 to 17 years with moderate to severe hidradenitis suppurativa HS. The study focuses on this condition, characterized by painful skin lesions, and aims to understand how the drug behaves in the body and its impact on disease symptoms over a 54-week treatment period. Participants will receive one of two doses of povorcitinib for 54 weeks in an open-label, non-randomized design. The study includes regular monitoring of drug levels in the blood up to Week 24. The two dose groups will help evaluate differences in treatment effects and safety over the full treatment duration. During the trial, participants will be assessed for adverse events, drug clearance, absorption, and concentration levels. The study will also measure clinical responses such as reduction in abscesses, inflammatory nodules, draining tunnels, skin pain, and quality of life changes using specific scales over 54 weeks. Safety and efficacy data will be collected throughout, with a primary focus on treatment-emergent adverse events and drug pharmacokinetics.
Actively Recruiting
This research aims to monitor the safety and effectiveness of the MAXX Orthopedics Freedom Total Knee System after it is on the market. It focuses on adult patients undergoing primary total knee arthroplasty TKA to meet regulatory requirements for ongoing product surveillance. The study includes up to 600 patients from about twenty registry sites, targeting an equal distribution of device types and aiming to enroll patients over approximately 10 months per site. Participants will receive the Freedom Total Knee System as part of their primary TKA procedure. The study tracks patients who have failed non-operative treatments and are scheduled for unilateral or bilateral primary TKA. The registry is observational, meaning the device is used as part of normal care, and participants are monitored over time. Recruitment includes up to 200 patients per device constraint level, and the study spans several years with data collection planned up to 24 months post-surgery. During the study, patients will complete various assessments including the Knee Society Scale, KOOS-JR, PROMIS Global-10, Visual Analog Scale, and Forgotten Joint Score at multiple timepoints from 3-6 weeks up to 24 months after surgery. Researchers will assess device survivorship over 2 years and monitor patient outcomes through questionnaires and clinical evaluations. The overall participation duration can extend up to several years, allowing for long-term safety and effectiveness data collection.